**About the Editors**

**Luciano Saso** is a member of the Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy (http://en.uniroma1.it/). He is the author of more than 250 original scientific articles published in peer-reviewed international journals (H-index Google Scholar = 47, H-index SCOPUS = 38), mainly in the field of oxidative stress and antioxidants. He has coordinated several international research projects and has been a referee for many national and international funding agencies and international scientific journals in the last 25 years. He has been a guest editor of several Special Issues in the fields of chemistry, biology, and pharmacology of modulators of oxidative stress.

**Hande Gurer-Orhan** obtained her BSc degree in Pharmacy in 1992, and her MSc degree (1994) and PhD degree (1999) in Toxicology from the University of Hacettepe, Turkey. She received a TUBITAK/NATO A2 grant and performed the laboratory work of her PhD thesis at the Department of Chemistry, University of Missouri-Rolla, USA. She worked as a post-doctoral fellow at the Medical School of Washington University, St Louis, MO in 2001 and at the Department of Molecular Toxicology, Vrije Universiteit during the period 2001–2003. She (https://avesis.ege.edu.tr/ hande.gurer.orhan) is currently working as a full professor and the head of the Toxicology Department at the Faculty of Pharmacy, Ege University, ˙Izmir, Turkey. She is a registered toxicologist in the European Union (ERT), a member of the Executive Committee of the Turkish Society of Toxicology, and a member of IUTOX and EUROTOX as well as the member of the Education Sub-Committee of EUROTOX. Her research interests are screening novel natural and synthetic endocrine modulating compounds, the assessment of their potential safety and efficiency for the treatment of hormone-related cancers and investigating the efficiency and toxicity of novel synthetic oxidative stress modulators, mainly melatonin analogues.

**Visnja ˇ Stepanic´** graduated and completed her MSc and PhD at the Faculty of Science of the University of Zagreb (Croatia). Afterwards, she joined the PLIVA Research Institute in 2002 and after its GlaxoSmithKline's (GSK) acquisition in 2006, she was a member of GSK Research Centre Zagreb. Since 2009, she has been a researcher at the Ruder Boskovi ˇ c´ Institute. She has participated in international scientific networks like COST actions. Her current main research interest includes (bio)chemical modulation of redox status with a focus on small molecular weight redox active natural and (semi)synthetic compounds with an optimized ADMET profile.
